Tag Archives: tumor testing

April 2014 Webinar: Alphabet Soup – Making Sense out of KRAS, BRAF and Tumor Tests

Have you ever heard any of these acronyms, and wondered what they stand for and how they can affect your treatment plan?  This webinar is designed to help patients better understand biomarkers, and how these biomarkers can affect the treatment options patients receive. We’ll discuss the basic understandings of a cancer cell lives, and how it dies.  As researchers are learning more and more about how to treat colorectal cancer, it is bringing the meaning of truly personalized medicine to the forefront. Join us to learn more, and how this research may affect your overall treatment plan. Presented by: Cathy Eng, M.D. Associate Professor, Department of Gastrointestinal (GI) Medical Oncology Dr.

July 2013 Webinar Molecular and Tumor Testing

Molecular Testing and Tumor Testing: Why is this important? In this presentation Dr. Bekaii-Saab, MD will discuss the importance of testing the molecular biology of an individual patients tumor. How they do that and why it may or may not be important to have done. He will talk about how this is playing an even bigger role in choice of treatment options for patients now more than ever. And about the way physicians are making treatment choices based on each individuals molecular biology of their tumor. Dr. Bekaii-Saab is the Section Chief, Gastrointestinal Oncology, James Cancer Hospital and Solove Research Institute. Dr. Bekaii-Saab is one of America’s Best Doctors. Additionally,

WEBINAR: Molecular Testing & Tumor Testing

Molecular testing and tumor testing — ever heard about it? Ever been asked about it? Join us for a Webinar on Wednesday, July 17 (8-9:30pm EDT) to learn more about these tools available for colorectal cancer patients. We’ll discuss: The importance of tumor testing and molecular testing. How this testing relates to colon and rectal cancer. If you should have your tumor tested. What tumor testing involves and how tumor testing is performed. The role tumor testing plays in a patient’s treatment options. Physicians making treatment choices based on a tumor’s molecular biology. REGISTER NOW About the presenter: Dr. Bekaii-Saab is the Section Chief, Gastrointestinal Oncology at James Cancer Hospital

Should All Colorectal Tumors Be Tested for Lynch Syndrome?

An international study described in the Oct. 17 Journal of the American Medical Association (JAMA) found that universal tumor testing in all newly diagnosed colorectal patients produced a “modest increase” in finding people with Lynch syndrome. One in every 35 people with colorectal cancer has Lynch syndrome – an inherited genetic mutation which greatly increases the person’s chance of developing colorectal cancer more than once, plus other cancers (stomach, pancreas, urinary system, brain or skin cancers). Women with Lynch syndrome also face a 40-60 percent chance of developing endometrial (uterine) cancer in their lifetime and an increased risk for ovarian cancer. Until genetic tests of tumors became available in recent

Screening Tumors for Lynch Syndrome is Cost-Effective

Screening all new colon and rectal cancer tumors for markers that might indicate Lynch syndrome not only saves future lives, it is cost effective according to a new study. In order for tumor screening to be cost-effective, not only should new tumors be tested, but family members need to follow through with genetic testing after a new Lynch mutation is found.  Finally people with Lynch syndrome mutations need to follow surveillance guidelines to prevent cancer or find it early, Testing both tumors and at least three to four family members could cost as little of $36,000 per life year saved — well within the value of preventive health strategies.

Top